Current Biology Impact Factor

Most disagreement is a source-label problem. The current 2026 JCR-derived exact-title record shows 7.7 for the 2025 Journal Impact Factor. Older public pages, cached titles, and secondary directories may still show 7.5 because that was the prior metric-year JIF. Scopus-side pages may show impact score, CiteScore, SJR, SNIP, or h-index near the JIF, but those metrics are not interchangeable with the Clarivate Journal Impact Factor.

Source limitation: this page uses current JCR-derived and Cell Press metric evidence for the 7.7 JIF. It uses secondary directories for historical or Scopus-side context only. If you need a CV, grant, or institutional report citation, verify the exact category rank and percentile directly in Journal Citation Reports.

The current JIF is up from 7.5 to 7.7, a 0.2-point increase, or about 2.7%, in the exact-title current record. The larger pattern is still a normalization from the 2020-2022 citation high, not a collapse in Current Biology's editorial position.

Trend guardrail: public historical rows can differ when they mix release year, metric year, rounded JIF, or stale cached snippets. Use the 2025 and 2024 rows for current source-bound comparison; use direct JCR access for formal year-by-year reporting.

Current Biology is a Q1 journal in current JCR-derived records, with category listings in Biochemistry & Molecular Biology, Biology, and Cell Biology. Exact ranks and percentiles can move by category and should be verified in JCR before formal use.

Do not mix Current Biology with similarly named "current biology" series, Current Opinion titles, or broader biology subject lists. The exact title is Current Biology, pISSN 0960-9822, eISSN 1879-0445, and JCR abbreviation CURR BIOL.

A 7.7 JIF tells you Current Biology remains a serious Q1 venue, but it does not make the journal a generic mid-tier biology outlet. Current Biology's value is not just the citation number. It is the combination of Cell Press editing, broad biological scope, concise article formats, strong commentary ecosystem, and a readership that spans cell biology, neuroscience, ecology, evolution, behavior, genetics, development, plant biology, and organismal biology.

The metric is easy to misread because 7.7 now sits near several other broad or selective biology journals. Current Biology is not simply "below Cell and above some specialist journals." It asks a different question: can the paper make a compact biological point that a non-specialist biologist would understand and care about quickly?

For authors, the practical read is this: the 7.7 JIF supports Current Biology as a high-quality target when the story is broad, surprising, and concise. It does not rescue a technically strong manuscript whose significance is obvious only to one subfield, whose main novelty is a method, or whose first figures require too much specialist setup before the biological consequence appears.

In our pre-submission review work on Current Biology manuscripts, the recurring issue is not usually whether the experiments are competent. The stronger signal is whether the title, abstract, first figure, article type, methods package, and cover letter make a broad-reader biological case quickly. Manusights guide-build evidence units for this page combine the metric-source ledger above with repeated Current Biology fit patterns we see before upload.

Current Biology mechanism paper with too little cross-biology consequence. We often see technically solid molecular, cellular, or neurobiology manuscripts where the result is real but the payoff stays inside one community. Current Biology can publish specialist methods and systems, but the first page still has to show what another kind of biologist learns. The abstract and Figure 1 need to surface the biological surprise before pathway detail or assay logic takes over.

Current Biology organismal paper that reads as descriptive rather than explanatory. Ecology, evolution, behavior, and organismal biology are real strengths for Current Biology. The weak pattern is a beautiful natural-history or behavioral result that does not change a broader model, mechanism, or principle. The manuscript needs to show why the finding travels beyond the focal organism, environment, or observational setup.

Current Biology article-type mismatch. Some manuscripts would be stronger as Reports, Articles, or specialist-journal submissions than as the shape authors first choose. Current Biology's article types reward compactness. When the core discovery needs four supplementary arguments to feel convincing, the problem is often story architecture, not only word count.

Current Biology Cell Press package friction. The metric attracts authors, but the first-read package still has to look like a Cell Press submission: clear Highlights/eTOC logic where required, transparent methods, resource availability, data availability, figure clarity, and a cover letter that names the cross-field interest. A paper can be high-quality and still feel like it was redirected from a narrower venue without being reframed.

A Current Biology readiness check can test whether the abstract, first figure, article type, methods, and cover letter support this target before upload.

Use official pages for mechanics, and use the fit logic above to decide whether the impact factor actually supports your target.

Current Biology at 7.7 is still a strong Q1 broad-biology journal. The current number is up slightly from 7.5, and the five-year JIF of 9.5 helps explain why the journal's author value is stronger than a two-year number alone suggests. The metric is enough to keep Current Biology on a serious shortlist, but it is not the reason to submit.

The right reason is fit: a compact biological discovery, readable across subfields, with a first figure and abstract that make the broader consequence obvious. If the manuscript is narrow, method-first, or dependent on specialist context, a different venue can be smarter even when Current Biology's JIF looks attractive.